Abstract 267: National Comparison of Prior Authorization and Utilization of Sacubitril/valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction

Aya F. Ozaki,Harlan M. Krumholz,Tien Tran,Quan Le,Mai Yokota,Freny Vaghaiwalla Mody,Cynthia A. Jackevicius

Abstract 267: National Comparison of Prior Authorization and Utilization of Sacubitril/valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction

2020

Aya F. Ozaki
Harlan M. Krumholz
Tien Tran
Quan Le
Mai Yokota
Freny Vaghaiwalla Mody
Cynthia A. Jackevicius

Background: Sacubitril/valsartan (Entresto®) reduces mortality and heart failure (HF) admissions in NYHA Class II/III HF with reduced ejection fraction (HFrEF). However, uptake in practice has been...

Keywords:

Ejection fraction
Heart failure
Prior authorization
in patient
Emergency medicine
Sacubitril, Valsartan
Medical emergency
Medicine
Sacubitril
Internal medicine
Physical therapy
Valsartan
nyha class
Cardiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations